MEROPENEM

Growth

meropenem

R-Pharm US
NDAINTRAVENOUSPOWDER
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

[ see Microbiology () ].

Indications (3)

bacterial meningitis caused by Haemophilus influenzaeNeisseria meningitidis andpenicillin-susceptible isolates of Streptococcus pneumoniaeolder

Clinical Trials (5)

NCT07327619Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP

Started Jan 2026
NCT07124468Phase 1Recruiting

Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

Started Sep 2025
NCT06916156Phase 1Completed

Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants

Started Apr 2025
NCT07089186Phase 3Recruiting

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

Started Apr 2025
NCT06342115Phase 4Recruiting

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

Started Mar 2025
176 enrolled
Febrile Neutropenia
Company
R-Pharm US
R-Pharm US
NJ - Princeton
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers